Sage Journals: Discover world-class research

Abstract

Introduction

High-dose catecholamines can impair hypoxic pulmonary vasoconstriction and increase shunt fraction. We aimed to determine if Angiotensin II (Ang-2) is associated with improved PaO₂/FiO₂ and SpO₂/FiO₂ in patients in shock.

Methods

Adult patients at four tertiary care centers and one community hospital in the United States who received Ang-2 from July 2018-September 2020 were included in this retrospective, observational cohort study. PaO₂, SpO₂, and FiO₂ were measured at 13 timepoints during the 48-h before and after Ang-2 initiation. Piecewise linear mixed models of PaO₂/FiO₂ and SpO₂/FiO₂ were created to evaluate hourly changes in oxygenation after Ang-2 initiation. The difference in the proportion of patients with PaO₂/FiO₂ ≤ 300 mm Hg at the time of Ang-2 initiation and 48 h after was also examined.

Results

The study included 254 patients. In the 48 h prior to Ang-2 initiation, oxygenation was significantly declining (hourly PaO₂/FiO₂ change −4.7 mm Hg/hr, 95% CI − 6.0 to −3.5, p < .001; hourly SpO₂/FiO₂ change −3.1/hr, 95% CI−3.7 to −2.4, p < .001). Ang-2 treatment was associated with significant improvements in PaO₂/FiO₂ and SpO₂/FiO₂ in the 48-h after initiation (hourly PaO₂/FiO₂ change +1.5 mm Hg/hr, 95% CI 0.5-2.5, p = .003; hourly SpO₂/FiO₂ change +0.9/hr, 95% CI 0.5-1.2, p < .001). The difference in the hourly change in oxygenation before and after Ang-2 initiation was also significant (p_interaction < 0.001 for both PaO₂/FiO₂ and SpO₂/FiO₂). This improvement was associated with significantly fewer patients having a PaO₂/FiO₂ ≤ 300 mm Hg at 48 h compared to baseline (mean difference −14.9%, 95% CI −25.3% to −4.6%, p = .011). Subgroup analysis found that patients with either a baseline PaO₂/FiO₂ ≤ 300 mm Hg or a norepinephrine-equivalent dose requirement >0.2 µg/kg/min had the greatest associations with oxygenation improvement.

Conclusions

Ang-2 is associated with improved PaO₂/FiO₂ and SpO₂/FiO₂. The mechanisms for this improvement are not entirely clear but may be due to catecholamine-sparing effect or may also be related to improved ventilation-perfusion matching, intrapulmonary shunt, or oxygen delivery.

Keywords

angiotensin II sepsis shock vasopressor renin-angiotensin-aldosterone-system acute respiratory distress syndrome oxygenation

Get full access to this article

View all access options for this article.

References

Levy

Evans

Rhodes

. The surviving sepsis campaign bundle: 2018 update. Crit Care Med. 2018;46(6):997‐1000.

De Backer

Biston

Devriendt

, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med. 2010;362(9):779‐789.

Levy

Evans

Rhodes

. The surviving sepsis campaign bundle: 2018 update. Intensive Care Med. 2018;44(6):925‐928.

Chow

Abuelkasem

Sankova

Henderson

Mazzeffi

Tanaka

. Reversal of vasodilatory shock: Current perspectives on conventional, rescue, and emerging vasoactive agents for the treatment of shock. Anesth Analg. 2020;130(1):15‐30.

Brown

Lanspa

Jones

, et al. Survival after shock requiring high-dose vasopressor therapy. Chest. 2013;143(3):664‐671.

Schmittinger

Torgersen

Luckner

Schroder

Lorenz

Dunser

. Adverse cardiac events during catecholamine vasopressor therapy: A prospective observational study. Intensive Care Med. 2012;38(6):950‐958.

Dunser

Mayr

Tur

, et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: Incidence and risk factors. Crit Care Med. 2003;31(5):1394‐1398.

Lumb

Slinger

. Hypoxic pulmonary vasoconstriction: Physiology and anesthetic implications. Anesthesiology. 2015;122(4):932‐946.

Papazian

Roch

Bregeon

, et al. Inhaled nitric oxide and vasoconstrictors in acute respiratory distress syndrome. Am J Respir Crit Care Med. 1999;160(2):473‐479.

10.

Davison

Chawla

Selassie

Tevar

Junker

Seneff

. Neurogenic pulmonary edema: Successful treatment with IV phentolamine. Chest. 2012;141(3):793‐795.

11.

Davison

Terek

Chawla

. Neurogenic pulmonary edema. Crit Care. 2012;16(2):212.

12.

Pineda Pompa

Barrera-Ramirez

Martinez-Valdez

Rodriguez

Guzman

. Pheochromocytoma-induced acute pulmonary edema and reversible catecholamine cardiomyopathy mimicking acute myocardial infarction. Rev Port Cardiol. 2004;23(4):561‐568.

13.

de Leeuw

Waltman

Birkenhager

. Noncardiogenic pulmonary edema as the sole manifestation of pheochromocytoma. Hypertension. 1986;8(9):810‐812.

14.

Khanna

English

Wang

, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017;377(5):419‐430.

15.

Smith

Newsome

Guo

, et al. A multicenter observational cohort study of angiotensin II in shock. J Intensive Care Med. 2022 Jan;37(1):75–82.

16.

Wieruszewski

Wittwer

Kashani

, et al. Angiotensin II infusion for shock: A multicenter study of postmarketing use. Chest. 2021;159(2):596‐605.

17.

Klijian

Khanna

Reddy

, et al. Treatment with angiotensin II is associated with rapid blood pressure response and vasopressor sparing in patients with vasoplegia after cardiac surgery: A post-hoc analysis of angiotensin II for the treatment of high-output shock (ATHOS-3) study. J Cardiothorac Vasc Anesth. 2021;35(1):51‐58.

18.

Zangrillo

Landoni

Beretta

, et al. Angiotensin II infusion in COVID-19-associated vasodilatory shock: A case series. Crit Care. 2020;24(1):227.

19.

Leisman

Mastroianni

Fisler

, et al. Physiologic response to angiotensin II treatment for coronavirus disease 2019-induced vasodilatory shock: A retrospective matched cohort study. Crit Care Explor. 2020;2(10):e0230.

20.

Bates

Mächler

Bolker

Walker

. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67(1):48.

21.

Pinheiro

Bates

DebRoy

Sarkar

, R Core Team. NLME: Linear and Nonlinear Mixed Effects Models. https://CRAN.R-project.org/package=nlme. Published 2021. Accessed 27-Feb, 2021.

22.

Fagerland

Lydersen

Laake

. Recommended tests and confidence intervals for paired binomial proportions. Stat Med. 2014;33(16):2850‐2875.

23.

Knaus

Draper

Wagner

Zimmerman

. APACHE II: A severity of disease classification system. Crit Care Med. 1985;13(10):818‐829.

24.

Force

ADT

Ranieri

Rubenfeld

, et al. Acute respiratory distress syndrome: The Berlin definition. JAMA. 2012;307(23):2526‐2533.

25.

Tumlin

Murugan

Deane

, et al. Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II. Crit Care Med. 2018;46(6):949‐957.

26.

Bellomo

Forni

Busse

, et al. Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock. A clinical trial. Am J Respir Crit Care Med. 2020;202(9):1253‐1261.

27.

Rassler

Contribution of alpha- and beta-adrenergic mechanisms to the development of pulmonary edema. Scientifica (Cairo). 2012;2012:829504.

28.

Busl

Bleck

. Neurogenic pulmonary edema. Crit Care Med. 2015;43(8):1710‐1715.

29.

McClellan

Dauber

Weil

. Elevated intracranial pressure increases pulmonary vascular permeability to protein. J Appl Physiol (Bethesda, Md : 1985). 1989;67(3):1185‐1191.

30.

Nathan

Reis

. Fulminating arterial hypertension with pulmonary edema from release of adrenomedullary catecholamines after lesions of the anterior hypothalamus in the rat. Circ Res. 1975;37(2):226‐235.

31.

Malik

. Mechanisms of neurogenic pulmonary edema. Circ Res. 1985;57(1):1‐18.

32.

Ducker

Simmons

. Increased intracranial pressure and pulmonary edema. 2. The hemodynamic response of dogs and monkeys to increased intracranial pressure. J Neurosurg. 1968;28(2):118‐123.

33.

Tarry

Powell

. Hypoxic pulmonary vasoconstriction. BJA Education. 2017;17(6):208‐213.

34.

Suggett

Mohammed

Barer

. Angiotensin, hypoxia, verapamil and pulmonary vessels. Clin Exp Pharmacol Physiol. 1980;7(3):263‐274.

35.

Alexander

Nyby

Jasberg

. Effect of angiotensin on hypoxic pulmonary vasoconstriction in isolated dog lung. J Appl Physiol. 1976;41(1):84‐88.

36.

Steven

. Hypoxic pulmonary vasoconstriction in the rat. Circ Res. 1974;35(2):256‐261.

37.

Hubloue

Rondelet

Kerbaul

, et al. Endogenous angiotensin II in the regulation of hypoxic pulmonary vasoconstriction in anaesthetized dogs. Crit Care. 2004;8(4):R163‐R171.

38.

Cargill

Lipworth

. Lisinopril attenuates acute hypoxic pulmonary vasoconstriction in humans. Chest. 1996;109(2):424‐429.

39.

Kiely

Cargill

Lipworth

. Acute hypoxic pulmonary vasoconstriction in man is attenuated by type I angiotensin II receptor blockade. Cardiovasc Res. 1995;30(6):875‐880.

40.

Vollmer

Meyers-Schoy

Marinelli

. Mechanisms involved in angiotensin II induced increases in cardiac output in pithed rats. Clin Exp Hypertens A. 1991;13(8):1433‐1445.

41.

Brown

Vaughan

. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97(14):1411‐1420.

42.

Dunser

Hasibeder

. Sympathetic overstimulation during critical illness: Adverse effects of adrenergic stress. J Intensive Care Med. 2009;24(5):293‐316.

43.

Holmes

Walley

Chittock

Lehman

Russell

. The effects of vasopressin on hemodynamics and renal function in severe septic shock: A case series. Intensive Care Med. 2001;27(8):1416‐1421.

44.

Klinzing

Simon

Reinhart

Bredle

Meier-Hellmann

. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med. 2003;31(11):2646‐2650.

45.

Dunser

Mayr

Ulmer

, et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: A retrospective analysis. Anesth Analg. 2001;93(1):7‐13.

46.

Luckner

Dunser

Jochberger

, et al. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med. 2005;33(11):2659‐2666.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB

Trajectory of PaO 2 /FiO 2 Ratio in Shock After Angiotensin II

Abstract

Introduction

Methods

Results

Conclusions

Keywords

Get full access to this article

References

Supplementary Material